TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
COSMO Pharmaceuticals N.V. ( (CH:COPN) ) has provided an update.
Cosmo Pharmaceuticals N.V. has announced the approval of its acne treatment, Winlevi®, by the Brazilian Health Authority, marking its entry into one of Latin America’s largest dermatology markets. This approval expands Winlevi®’s availability to over 50% of the Latin American population and strengthens Cosmo’s global dermatology presence. The product, which offers a novel approach to acne treatment without systemic hormonal effects, is set to be launched in Brazil by Sun Pharmaceutical Industries Limited. This milestone supports Cosmo’s Vision 2030 growth strategy and enhances its partnership with Sun Pharma.
The most recent analyst rating on (CH:COPN) stock is a Hold with a CHF67.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.
More about COSMO Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V. is a life-science company specializing in MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing. Founded in 1997 and headquartered in Dublin, Ireland, Cosmo is committed to creating advanced medical solutions that address critical health needs and improve care standards globally. The company collaborates with leading pharma and MedTech firms to deliver innovative products to patients and healthcare providers worldwide.
Average Trading Volume: 19,544
Technical Sentiment Signal: Buy
Current Market Cap: CHF1.11B
For an in-depth examination of COPN stock, go to TipRanks’ Overview page.